Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma

British Journal of Haematology

Volumn 151, Issue 4, 2010, Pages 381-386

  Klintman, Jenny ^a   Astermark, Jan ^a   Berntorp, Erik ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

By passing agents; Factor VIII concentrates; Haemophilia A; Inhibitors; Thrombin generation

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING INHIBITOR; FANHDI; HAEMATE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBIN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFECT; DRUG POTENTIATION; HEMOPHILIA A; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL;

AUTOANTIBODIES; BLOOD COAGULATION FACTORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG SYNERGISM; FACTOR VIIA; FACTOR VIII; HEMOPHILIA A; HUMANS; RECOMBINANT PROTEINS; THROMBIN;

EID: 77958575112     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08378.x     Document Type: Article

References (30)

1. Astermark, J. (2003) Treatment of the bleeding inhibitor patient. Seminars in Thrombosis and Hemostasis, 29, 77-86.
2. Berntorp, E. (2007) VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice. Haemophilia, 13, 69-72.
3. Berntorp, E. (2009) Haemate P/Humate-P: a systematic review. Thrombosis Research, 124(Suppl. 1), S11-S14.
4. Dargaud, Y., Lienhart, A., Meunier, S., Hequet, O., Chavanne, H., Chamouard, V., Marin, S. & Negrier, C. (2005) Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Haemophilia, 11, 552-558.
5. Economou, M., Teli, A., Tzantzaroudi, A., Tsatra, I., Zavitsanakis, A. & Athanassiou-Metaxa, M. (2008) Sequential therapy with activated prothrombin complex concentrate (FEIBA) and recombinant factor VIIa in a patient with severe haemophilia A, inhibitor presence and refractory bleeding. Haemophilia, 14, 390-391.
6. Gensana, M., Altisent, C., Aznar, J.A., Casana, P., Hernandez, F., Jorquera, J.I., Magallon, M., Massot, M. & Puig, L. (2001) Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia, 7, 369-374.
7. Gomperts, E.D., Astermark, J., Gringeri, A. & Teitel, J. (2008) From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia A patients with inhibitors. Blood Reviews, 22, S1-S11.
8. Goudemand, J., Rothschild, C., Demiguel, V., Vinciguerrat, C., Lambert, T., Chambost, H., Borel-Derlon, A., Claeyssens, S., Laurian, Y. & Calvez, T. (2006) Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood, 107, 46-51.
9. Habermann, B., Hochmuth, K., Hovy, L., Scharrer, I. & Kurth, A.H. (2004) Management of haemophilic patients with inhibitors in major orthopaedic surgery by immunadsorption, substitution of factor VIII and recombinant factor VIIa (NovoSeven): a single centre experience. Haemophilia, 10, 705-712.
10. Kallas, A. & Talpsep, T. (2001) von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia, 7, 375-380.
11. Key, N.S., Christie, B., Henderson, N. & Nelsestuen, G.L. (2002) Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy. Thrombosis and Haemostasis, 88, 60-65.
12. Livnat, T., Martinowitz, U., Zivelin, A. & Seligsohn, U. (2008) Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma. Haemophilia, 14, 782-786.
13. Logan, L.J. (2009) von Willebrand factor content in Alphanate. Haemophilia, 15, 369; author reply 370-361.
14. Mackman, N. (2009) The role of tissue factor and factor VIIa in hemostasis. Anesthesia and Analgesia, 108, 1447-1452.
15. Martinowitz, U., Livnat, T., Zivelin, A. & Kenet, G. (2009) Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Haemophilia, 15, 904-910.
16. Monroe, D.M., Hoffman, M., Oliver, J.A. & Roberts, H.R. (1997) Platelet activity of high-dose factor VIIa is independent of tissue factor. British Journal of Haematology, 99, 542-547.
17. Monroe, D.M., Hoffman, M., Oliver, J.A. & Roberts, H.R. (1998) A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagulation and Fibrinolysis, 9(Suppl. 1), S15-S20.
18. Nilsson, I.M. & Hedner, U. (1976) Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX. Scandinavian Journal of Haematology, 16, 369-382.
19. Pipe, S.W. & Valentino, L.A. (2007) Optimizing outcomes for patients with severe haemophilia A. Haemophilia, 13(Suppl. 4), 1-16.
20. Ristol, P., Gensana, M., Fernandez, J., Massot, M., Bhattacharya, P. & Jorquera, J.I. (1996) [Development and characterization of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)]. Sangre (Barc), 41, 125-130.
21. Salvagno, G.L., Astermark, J., Ekman, M., Franchini, M., Guidi, G.C., Lippi, G., Poli, G. & Berntorp, E. (2007) Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation. Haemophilia, 13, 51-56.
22. Schneiderman, J., Rubin, E., Nugent, D.J. & Young, G. (2007) Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia, 13, 244-248.
23. Tellier, Z., Andre, M.H. & Polack, B. (2009) Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives. Clinical Reviews in Allergy and Immunology, 37, 125-134.
24. Tomokiyo, K., Nakatomi, Y., Araki, T., Teshima, K., Nakano, H., Nakagaki, T., Miyamoto, S., Funatsu, A. & Iwanaga, S. (2003) A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone. Vox Sanguinis, 85, 290-299.
25. Turecek, P.L., Varadi, K., Gritsch, H. & Schwarz, H.P. (2004a) FEIBA: mode of action. Haemophilia, 10, S3-S9.
26. Turecek, P.L., Varadi, K. & Schwarz, H.P. (2004b) Update on the mechanism of action and future of activated prothrombin complex concentrates. Current Hematology Reports, 3, 331-337.
27. Varadi, K., Siekmann, J., Turecek, P.L., Schwarz, H.P. & Marder, V.J. (1999) Phospholipid-bound tissue factor modulates both thrombin generation and APC-mediated factor Va inactivation. Thrombosis and Haemostasis, 82, 1673-1679.
28. Varadi, K., Negrier, C., Berntorp, E., Astermark, J., Bordet, J.C., Morfini, M., Linari, S., Schwarz, H.P. & Turecek, P.L. (2003) Monitoring the bioavailability of FEIBA with a thrombin generation assay. Journal of Thrombosis and Haemostasis, 1, 2374-2380.
29. Varadi, K., Turecek, P.L. & Schwarz, H.P. (2004) Thrombin generation assay and other universal tests for monitoring haemophilia therapy. Haemophilia, 10, 17-21.
30. Van Veen, J.J., Gatt, A., Bowyer, A.E., Cooper, P.C., Kitchen, S. & Makris, M. (2009) The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents. International Journal of Laboratory Hematology, 31, 189-198.